Considering that shortened telomeres are linked to higher risks of IPF, telomerase activators such as TA-65 (96), which counteract telomere shortening linked to IPF progression could be studied in IPF, alone and in combination with inhibitors of PI3K/Akt. Here, AKT1 is linked to idiopathic pulmonary fibrosis.